248 related articles for article (PubMed ID: 8995510)
61. Cisplatin-induced nephrotoxicity and the protective effect of fosfomycin on it as demonstrated by using a crossover study of urinary metabolite levels.
Hayashi M; Numaguchi M; Watabe H; Enomoto H; Yaoi Y
Acta Obstet Gynecol Scand; 1997 Jul; 76(6):590-5. PubMed ID: 9246969
[TBL] [Abstract][Full Text] [Related]
62. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).
Ikeda H; Nagashima K; Okumura H; Takahashi A; Matsuyama S; Nagamachi Y
Eur J Surg Oncol; 1988 Feb; 14(1):17-20. PubMed ID: 3278937
[TBL] [Abstract][Full Text] [Related]
63. Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.
Monjanel-Mouterde S; Frenay C; Catalin J; Boutin C; Durand A; Astoul P
Oncol Rep; 2000; 7(1):171-5. PubMed ID: 10601613
[TBL] [Abstract][Full Text] [Related]
64. Prevention of nephrotoxicity of cisplatin by repeated oral administration of ebselen in rats.
Yoshida M; Iizuka K; Terada A; Hara M; Nishijima H; Akinori ; Shimada ; Nakada K; Satoh Y; Akama Y
Tohoku J Exp Med; 2000 Aug; 191(4):209-20. PubMed ID: 11038013
[TBL] [Abstract][Full Text] [Related]
65. Involvement of indoxyl sulfate in renal and central nervous system toxicities during cisplatin-induced acute renal failure.
Iwata K; Watanabe H; Morisaki T; Matsuzaki T; Ohmura T; Hamada A; Saito H
Pharm Res; 2007 Apr; 24(4):662-71. PubMed ID: 17318420
[TBL] [Abstract][Full Text] [Related]
66. Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations.
Reece PA; Stafford I; Abbott RL; Anderson C; Denham J; Freeman S; Morris RG; Gill PG; Olweny CL
J Clin Oncol; 1989 Feb; 7(2):270-5. PubMed ID: 2536803
[TBL] [Abstract][Full Text] [Related]
67. [Cis-diamminedichloroplatinum penetration into the cerebrospinal fluid of the lateral ventricle, postoperative cavity, and lumbar subarachnoid space with or without pre-intravenous mannitol administration in patients with brain metastasis from lung cancer].
Nakagawa H; Yamada M; Tamura M; Yoshida M; Shindo M; Nishiyama H; Sakai S
Gan To Kagaku Ryoho; 2014 Mar; 41(3):317-24. PubMed ID: 24743276
[TBL] [Abstract][Full Text] [Related]
68. Platinum pharmacokinetics in sulphur-crested cockatoos (Cacatua galerita) following single-dose cisplatin infusion.
Filippich LJ; Bucher AM; Charles BG
Aust Vet J; 2000 Jun; 78(6):406-11. PubMed ID: 10920780
[TBL] [Abstract][Full Text] [Related]
69. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
[TBL] [Abstract][Full Text] [Related]
70. [Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma].
Goto T; Yoshimura K; Matsui Y; Shimizu Y; Inoue T; Okubo K; Kamba T; Nishiyama H; Ogawa O
Hinyokika Kiyo; 2011 Dec; 57(12):671-6. PubMed ID: 22240299
[TBL] [Abstract][Full Text] [Related]
71. [A study of CDDP in the treatment of patients with gastric and esophageal cancers, with special reference to the evaluation of renal functions before and after CDDP administration].
Sasaki E; Namatame K; Hirose C; Hamai N; Onomura Y; Miyata N; Kusumoto S; Makuuchi M; Iwai H; Asakawa K
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2713-7. PubMed ID: 3415269
[TBL] [Abstract][Full Text] [Related]
72. [Relationship between plasma and urinary platinum pharmacokinetics with cisplatin nephrotoxicity in breast cancer patients].
Guo JH
Zhonghua Zhong Liu Za Zhi; 1992 Mar; 14(2):150-3. PubMed ID: 1618086
[TBL] [Abstract][Full Text] [Related]
73. Pharmacokinetic behaviour of cisplatin in peritoneal fluid after intraperitoneal administration of cisplatin-loaded microspheres.
Tamura T; Imai J; Matsukawa Y; Horikiri Y; Suzuki T; Yoshino H; Ike O
J Pharm Pharmacol; 2001 Oct; 53(10):1331-9. PubMed ID: 11697540
[TBL] [Abstract][Full Text] [Related]
74. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
Reece PA; Stafford I; Russell J; Gill PG
J Clin Oncol; 1986 Sep; 4(9):1392-8. PubMed ID: 3746376
[TBL] [Abstract][Full Text] [Related]
75. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
76. Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors.
Delord JP; Puozzo C; Lefresne F; Bugat R
Anticancer Res; 2009 Feb; 29(2):553-60. PubMed ID: 19331202
[TBL] [Abstract][Full Text] [Related]
77. Constancy in integrated cisplatin plasma concentrations among pediatric patients.
Goodisman J; Souid AK
J Clin Pharmacol; 2006 Apr; 46(4):443-8. PubMed ID: 16554452
[TBL] [Abstract][Full Text] [Related]
78. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function.
Yamamoto N; Tamura T; Maeda M; Ando M; Shinkai T; Eguchi K; Ohe Y; Oshita F; Shiraishi J; Katsumata N
Cancer Chemother Pharmacol; 1995; 36(2):102-6. PubMed ID: 7767944
[TBL] [Abstract][Full Text] [Related]
79. Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment.
Ogawa T; Niho S; Nagai S; Kojima T; Nishimura Y; Ohe Y; Kondo N; Yamaguchi T; Endo K; Izumi K; Minami H
Int J Clin Oncol; 2013 Dec; 18(6):977-82. PubMed ID: 23053402
[TBL] [Abstract][Full Text] [Related]
80. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.
Usui T; Oiso Y; Tomita A; Ogata E; Uchida T; Ikeda K; Watanabe T; Higuchi S
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):239-44. PubMed ID: 9208339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
